Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment.

导出 OA

翻译打印收藏纠错

作者： Folnetti A,Alvarez ^[1] ; Hussein,Kaddour ^[1] ; Yuan,Lyu ^[2] ; Christina,Preece ^[1] ; Jules,Cohen ^[3] ; Lea,Baer ^[4] ; Alison T,Stopeck ^[5] ; Patricia,Thompson ^[6] ; Chioma M,Okeoma ^[7]

作者单位： Department of Pharmacology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794-8651, USA. ^[1] Regeneron Pharmaceuticals, Inc, Tarrytown, NY, 10591, USA. ^[2] Medical Research Center, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. ^[3] Department of Pathology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794-8651, USA. ^[4] Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, 90048, USA. ^[5] Department of Medicine, Division of Hematology and Medical Oncology, Stony Brook University, Stony Brook, NY, 11794-8651, USA. ^[6] Stony Brook University Cancer Center, Stony Brook, NY, 11794-8651, USA. ^[7] Department of Pharmacology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794-8651, USA. chioma.okeoma@stonybrook.edu. ^[8] Department of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, NY, 10595-1524, USA. chioma.okeoma@stonybrook.edu. ^[9]

关键词 BEVs Biomarkers Breast cancer Chemoresistance Neoadjuvant chemotherapy PPLC